Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Free Thinking: Leveraging the ASEAN Market

July 9, 2014 | ASEAN, Asia, emerging markets 

If you can only research one ASEAN market, which one do you choose?Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to consider in deciding which markets to research.

Home to over half a billion people, the 10 nations that make up the ASEAN region constitute the eighth largest economy in the world. With pharmaceutical sales projected to exceed $20 billion in 2014, it’s an increasingly attractive and dynamic growth market for pharma manufacturers.

But with pharmaceutical market researchers being subjected to ever tighter budgets and timelines, conducting research in all ASEAN markets is rarely a viable option.

A common question amongst our clients interested in leveraging opportunities within the ASEAN markets is ‘if I can research only one ASEAN market for my product, how do I go about choosing one?’ A seemingly straightforward question, yet one which is actually quite difficult to answer.

Download and read the complimentary whitepaper at http://bit.ly/1IJ86oO

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges. 

This content was provided by Research Partnership

Company Details

- PMLiVE

Research Partnership

Email
Website

 Latest Content from  Research Partnership 

New syndicated COPD report now available

Living with COPD 2023

Man vs microbe: the fight against antimicrobial resistance

How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics.

Research Partnership Senior Director Andrew Stokes appointed new role as Chief Commercial Officer

With over 20 years' experience in the industry, Research Partnership Senior Director and market research veteran Andrew Stokes has been appointed Chief Commercial Officer.

Case study: How we enhanced the power of a global ATU using our advanced analytics solution, Equity AI

Find out how we provided a more holistic understanding of brand equity and a forward indication of potential market share using our advanced analytics solution, Equity AI.

Article: Creating truly effective communications – the impact of high speed, high octane messaging

In a recent interview for PME Magazine, Roy Rogers shows how to navigate the busy omnichannel communication lanes to make the best of digital.

Research Partnership makes two senior appointments to bolster its US and MedTech operations

Research Partnership is delighted to announce the appointments of Sue Wild as President, US Pharma in the US and Tom Donnelly as a Director in the US MedTech division.

Case study: How segmentation of treaters guided a novel product launch in the allergy space

Find out how we helped our client to obtain an intuitive and actionable segmentation in order to drive market shaping activities ahead of their product launch aimed at the treatment...

Article: War in the Blood – The battle takes shape in the burgeoning European oncology CAR-T market access space

Tania Rodrigues investigates the market access and commercialization potential for manufacturers of CAR-T therapies in the latest issue of pharmaphorum's Deep Dive.

Research Partnership wins prestigious 2023 BOBI Award

We are delighted to announce Research Partnership were announced the winners in the ‘Creative Fieldwork Team of the Year’ category at the BHBIA’s Best of Business Intelligence (BOBI) Awards.

Case study: How we provided in-depth knowledge of electrosurgical generators among target segments and settings in the US market

Find out how we helped our client to identify clinician roles and responsibilities, pain points and drivers and barriers with respect to a current medical device.